2025
Renalase levels are decreased in maternal blood and placental tissues in pregnancies associated with preterm preeclampsia
Soliman Y, Eke C, Guo X, Wang M, Silva T, Désir G, Konnikova L. Renalase levels are decreased in maternal blood and placental tissues in pregnancies associated with preterm preeclampsia. Scientific Reports 2025, 15: 6480. PMID: 39987333, PMCID: PMC11846959, DOI: 10.1038/s41598-025-90524-z.Peer-Reviewed Original ResearchConceptsCases of preeclampsiaSerum renalasePreterm casesRenalase levelsPregnancies associated with hypertensionFactors associated with preeclampsiaRisk of eclampsiaPathophysiology of preeclampsiaLevels of renalasePreterm preeclampsiaTerm preeclampsiaMaternal serumMaternal bloodRenalase expressionPlacental villiPreeclampsiaPlacental tissuePretermPlacentaRenalaseMaternal healthPregnancyHypertensionSerumVariable effects
2019
Early Preterm Preeclampsia Outcomes by Intended Mode of Delivery
Coviello E, Iqbal S, Grantz K, Huang C, Landy H, Reddy U. Early Preterm Preeclampsia Outcomes by Intended Mode of Delivery. Obstetric Anesthesia Digest 2019, 39: 187-188. DOI: 10.1097/01.aoa.0000603672.77426.4d.Peer-Reviewed Original ResearchSevere featuresEarly preterm deliveryEarly preterm preeclampsiaEarly preterm birthElevated liver enzymesSyndrome of hemolysisIntended modePreeclampsia outcomesNeonatal outcomesPregnant patientsPreterm deliveryPreterm preeclampsiaPreterm birthLow plateletsMaternal mortalityLiver enzymesPaucity of studiesPreeclampsiaOutcomesDeliveryEclampsiaMorbidityPatientsPregnancySyndromeGottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States: Think Tank Summary.
Copel JA, Platt LD, Hobbins JC, Afshar Y, Grechukhina O, Mallampati D, Bromley B, Caughey AB, Grobman W, Han CS, Nicolaides K, Pettker C, Saade G, Sibai B, Simhan H, Sonek J, Werner E, Chescheir N. Gottesfeld-Hohler Memorial Foundation Risk Assessment for Early-Onset Preeclampsia in the United States: Think Tank Summary. Obstetrics And Gynecology 2019, 135: 36-45. PMID: 31809427, DOI: 10.1097/aog.0000000000003582.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsEarly-onset preeclampsiaSubstantial economic burdenCost-effectiveness dataAspirin prophylaxisNeonatal morbidityPreterm preeclampsiaProphylactic usePreventive strategiesEconomic burdenPreeclampsiaCurrent professional guidelinesRisk assessment strategiesRisk assessmentPractice changeDifferent assessment toolsSpecific knowledge gapsAspirinUnited StatesTarget populationConsequent interventionsFeasibility of implementationProfessional guidelinesAssessment toolAvailable literatureRisk
2017
LB02: Randomized double-blind placebo controlled evaluation of the safety and efficacy of recombinant Antithrombin versus placebo in preterm preeclampsia
Sibai B, Paidas M, Group T. LB02: Randomized double-blind placebo controlled evaluation of the safety and efficacy of recombinant Antithrombin versus placebo in preterm preeclampsia. American Journal Of Obstetrics And Gynecology 2017, 216: s559-s560. DOI: 10.1016/j.ajog.2016.11.1048.Peer-Reviewed Original Research
2013
Exploring the Role of Antithrombin Replacement for the Treatment of Preeclampsia: A Prospective Randomized Evaluation of the Safety and Efficacy of Recombinant Antithrombin in Very Preterm Preeclampsia (PRESERVE‐1)
Paidas MJ, Sibai BM, Triche EW, Frieling J, Lowry S, Group T. Exploring the Role of Antithrombin Replacement for the Treatment of Preeclampsia: A Prospective Randomized Evaluation of the Safety and Efficacy of Recombinant Antithrombin in Very Preterm Preeclampsia (PRESERVE‐1). American Journal Of Reproductive Immunology 2013, 69: 539-544. PMID: 23444920, DOI: 10.1111/aji.12091.Peer-Reviewed Original ResearchConceptsProspective Randomized EvaluationAntithrombin replacementWeeks' gestationRandomized EvaluationRecombinant antithrombinTreatment of preeclampsiaRecombinant human ATExpectant managementPreterm preeclampsiaPrimary endpointMaternal indicationsGestational ageStudy enrollmentAT therapyPreeclampsia studyPreeclampsiaGestationHuman ATAT replacementPharmacokinetic activityAntithrombinEfficacySafetyLaboratory assaysDelivery
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply